Mast Cells' integrated actions with eosinophils and fibroblasts in allergic inflammation: Implications for therapy

Nadine Landolina; Roopesh Singh Gangwar; Francesca Levi-Schaffer

doi:10.1016/bs.ai.2014.09.002

Mast Cells' integrated actions with eosinophils and fibroblasts in allergic inflammation: Implications for therapy

Nadine Landolina, Roopesh Singh Gangwar, Francesca Levi-Schaffer^*

^*Corresponding author for this work

School of Pharmacy

Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review

32 Scopus citations

Abstract

Mast cells (MCs) and eosinophils (Eos) are the key players in the development of allergic inflammation (AI). Their cross-talk, named the Allergic Effector Unit (AEU), takes place through an array of soluble mediators and ligands/receptors interactions that enhance the functions of both the cells. One of the salient features of the AEU is the CD48/2B4 receptor/ligand binding complex. Furthermore, MCs and Eos have been demonstrated to play a role not only in AI but also in the modulation of its consequence, i.e., fibrosis/tissue remodeling, by directly influencing fibroblasts (FBs), the main target cells of these processes. In turn, FBs can regulate the survival, activity, and phenotype of both MCs and Eos. Therefore, a complex three players, MCs/Eos/FBs interaction, can take place in various stages of AI. The characterization of the soluble and physical mediated cross talk among these three cells might lead to the identification of both better and novel targets for the treatment of allergy and its tissue remodeling consequences.

Original language	American English
Title of host publication	Advances in Immunology
Publisher	Academic Press Inc.
Pages	41-85
Number of pages	45
Edition	1
DOIs	https://doi.org/10.1016/bs.ai.2014.09.002
State	Published - 2015

Publication series

Name	Advances in Immunology
Number	1
Volume	125
ISSN (Print)	0065-2776
ISSN (Electronic)	1557-8445

Bibliographical note

Funding Information:
F. L.-S. acknowledges grant support from a “Kamin” grant of the Israel Ministry of Industry (File no. 46223), the Israel Science Foundation (Grant 699/10), MAARS EU 7th framework (Grant No. HEALTH-F2-2011-261366), and the Aimwell Charitable Trust Foundation (UK). F. L.-S. is a member of the Dr. Adolph and Klara Brettler Center for Research in Molecular Pharmacology and Therapeutics, and the David R. Bloom Center for Pharmacy at The Hebrew University of Jerusalem's School of Pharmacy. We wish to thank Madelyn Segev for her secretarial and editing assistance.

Publisher Copyright:
© 2015 Elsevier Inc.

Keywords

Allergic Effector Unit
Allergic inflammation
Asthma
Eosinophils
Fibroblast
Fibrosis
Interaction
Mast cells

Access to Document

10.1016/bs.ai.2014.09.002

Cite this

@inbook{7f629007e7814bd3918b33813b018a1d,

title = "Mast Cells' integrated actions with eosinophils and fibroblasts in allergic inflammation: Implications for therapy",

abstract = "Mast cells (MCs) and eosinophils (Eos) are the key players in the development of allergic inflammation (AI). Their cross-talk, named the Allergic Effector Unit (AEU), takes place through an array of soluble mediators and ligands/receptors interactions that enhance the functions of both the cells. One of the salient features of the AEU is the CD48/2B4 receptor/ligand binding complex. Furthermore, MCs and Eos have been demonstrated to play a role not only in AI but also in the modulation of its consequence, i.e., fibrosis/tissue remodeling, by directly influencing fibroblasts (FBs), the main target cells of these processes. In turn, FBs can regulate the survival, activity, and phenotype of both MCs and Eos. Therefore, a complex three players, MCs/Eos/FBs interaction, can take place in various stages of AI. The characterization of the soluble and physical mediated cross talk among these three cells might lead to the identification of both better and novel targets for the treatment of allergy and its tissue remodeling consequences.",

keywords = "Allergic Effector Unit, Allergic inflammation, Asthma, Eosinophils, Fibroblast, Fibrosis, Interaction, Mast cells",

author = "Nadine Landolina and Gangwar, {Roopesh Singh} and Francesca Levi-Schaffer",

note = "Funding Information: F. L.-S. acknowledges grant support from a “Kamin” grant of the Israel Ministry of Industry (File no. 46223), the Israel Science Foundation (Grant 699/10), MAARS EU 7th framework (Grant No. HEALTH-F2-2011-261366), and the Aimwell Charitable Trust Foundation (UK). F. L.-S. is a member of the Dr. Adolph and Klara Brettler Center for Research in Molecular Pharmacology and Therapeutics, and the David R. Bloom Center for Pharmacy at The Hebrew University of Jerusalem's School of Pharmacy. We wish to thank Madelyn Segev for her secretarial and editing assistance. Publisher Copyright: {\textcopyright} 2015 Elsevier Inc.",

year = "2015",

doi = "10.1016/bs.ai.2014.09.002",

language = "American English",

series = "Advances in Immunology",

publisher = "Academic Press Inc.",

number = "1",

pages = "41--85",

booktitle = "Advances in Immunology",

address = "United States",

edition = "1",

}

Mast Cells' integrated actions with eosinophils and fibroblasts in allergic inflammation: Implications for therapy. / Landolina, Nadine; Gangwar, Roopesh Singh; Levi-Schaffer, Francesca.
Advances in Immunology. 1. ed. Academic Press Inc., 2015. p. 41-85 (Advances in Immunology; Vol. 125, No. 1).

Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review

TY - CHAP

T1 - Mast Cells' integrated actions with eosinophils and fibroblasts in allergic inflammation

T2 - Implications for therapy

AU - Landolina, Nadine

AU - Gangwar, Roopesh Singh

AU - Levi-Schaffer, Francesca

N1 - Funding Information: F. L.-S. acknowledges grant support from a “Kamin” grant of the Israel Ministry of Industry (File no. 46223), the Israel Science Foundation (Grant 699/10), MAARS EU 7th framework (Grant No. HEALTH-F2-2011-261366), and the Aimwell Charitable Trust Foundation (UK). F. L.-S. is a member of the Dr. Adolph and Klara Brettler Center for Research in Molecular Pharmacology and Therapeutics, and the David R. Bloom Center for Pharmacy at The Hebrew University of Jerusalem's School of Pharmacy. We wish to thank Madelyn Segev for her secretarial and editing assistance. Publisher Copyright: © 2015 Elsevier Inc.

PY - 2015

Y1 - 2015

N2 - Mast cells (MCs) and eosinophils (Eos) are the key players in the development of allergic inflammation (AI). Their cross-talk, named the Allergic Effector Unit (AEU), takes place through an array of soluble mediators and ligands/receptors interactions that enhance the functions of both the cells. One of the salient features of the AEU is the CD48/2B4 receptor/ligand binding complex. Furthermore, MCs and Eos have been demonstrated to play a role not only in AI but also in the modulation of its consequence, i.e., fibrosis/tissue remodeling, by directly influencing fibroblasts (FBs), the main target cells of these processes. In turn, FBs can regulate the survival, activity, and phenotype of both MCs and Eos. Therefore, a complex three players, MCs/Eos/FBs interaction, can take place in various stages of AI. The characterization of the soluble and physical mediated cross talk among these three cells might lead to the identification of both better and novel targets for the treatment of allergy and its tissue remodeling consequences.

AB - Mast cells (MCs) and eosinophils (Eos) are the key players in the development of allergic inflammation (AI). Their cross-talk, named the Allergic Effector Unit (AEU), takes place through an array of soluble mediators and ligands/receptors interactions that enhance the functions of both the cells. One of the salient features of the AEU is the CD48/2B4 receptor/ligand binding complex. Furthermore, MCs and Eos have been demonstrated to play a role not only in AI but also in the modulation of its consequence, i.e., fibrosis/tissue remodeling, by directly influencing fibroblasts (FBs), the main target cells of these processes. In turn, FBs can regulate the survival, activity, and phenotype of both MCs and Eos. Therefore, a complex three players, MCs/Eos/FBs interaction, can take place in various stages of AI. The characterization of the soluble and physical mediated cross talk among these three cells might lead to the identification of both better and novel targets for the treatment of allergy and its tissue remodeling consequences.

KW - Allergic Effector Unit

KW - Allergic inflammation

KW - Asthma

KW - Eosinophils

KW - Fibroblast

KW - Fibrosis

KW - Interaction

KW - Mast cells

UR - http://www.scopus.com/inward/record.url?scp=84922336433&partnerID=8YFLogxK

U2 - 10.1016/bs.ai.2014.09.002

DO - 10.1016/bs.ai.2014.09.002

M3 - Chapter

C2 - 25591464

AN - SCOPUS:84922336433

T3 - Advances in Immunology

SP - 41

EP - 85

BT - Advances in Immunology

PB - Academic Press Inc.

ER -

Mast Cells' integrated actions with eosinophils and fibroblasts in allergic inflammation: Implications for therapy

Abstract

Publication series

Bibliographical note

Keywords

Access to Document

Other files and links

Fingerprint

Cite this